Профілактика дисемінованого комплексу Mycobacterium avium (MAC) у ВІЛ-інфікованих пацієнтів — від порогу CD4 до відміни профілактики на тлі АРТ
Mycobacterium avium complex (MAC) — principally M. avium and M. intracellulare — are ubiquitous environmental organisms found in soil, water, and dust. In people with intact immunity they rarely cause disease. But in the setting of profound, sustained immunosuppression, MAC can disseminate from the gut and respiratory mucosa into the bloodstream, bone marrow, liver, and spleen. Decades of AIDS-era cohort data established that this risk is not linear — it rises sharply once CD4 counts fall below roughly 50 cells/mm³, marking a recognized threshold for clinical concern and, historically, a trigger for preventive therapy.
MAC organisms are low-virulence environmental mycobacteria that healthy cell-mediated immunity — chiefly CD4+ T-lymphocyte-driven macrophage activation — keeps contained at mucosal surfaces. As CD4 counts decline, this containment progressively fails:
• CD4 200–500: MAC exposure essentially inconsequential; no meaningful excess risk • CD4 50–200: localized or subclinical colonization possible; disseminated disease uncommon • CD4 <50: macrophage activation and granuloma formation collapse; MAC can translocate across gut mucosa into the bloodstream and seed the reticuloendothelial system
In the pre-ART era, cohort studies showed cumulative incidence of disseminated MAC disease approaching 20–40% among patients who survived long enough at CD4 <50, making it one of the defining opportunistic infections of late-stage untreated HIV, alongside CMV retinitis and cryptosporidiosis.
Disseminated MAC classically presents with non-specific but debilitating systemic features: persistent fevers, drenching night sweats, profound weight loss, fatigue, and abdominal pain from hepatosplenomegaly or mesenteric lymphadenopathy. Laboratory findings often include significant anemia (from bone marrow involvement) and elevated alkaline phosphatase.
Because symptoms overlap with many other advanced-HIV processes (lymphoma, other disseminated infections, HIV wasting itself), diagnosis historically required a high index of suspicion plus blood or bone marrow mycobacterial cultures. Before effective ART, disseminated MAC carried substantial independent mortality risk and markedly worsened quality of life in the final stage of untreated AIDS.
For much of the 1990s, primary MAC prophylaxis (typically azithromycin or clarithromycin) was routinely recommended for essentially all patients with CD4 <50, regardless of ART status, because ART access and potency were limited and CD4 recovery was slow or uncertain. That calculus has fundamentally changed. With widely available, highly effective, well-tolerated combination ART, CD4 counts now recover quickly and reliably for most patients who start and adhere to therapy — and ART itself is a far stronger, more durable protection against MAC than any antibiotic prophylaxis regimen.
Three converging factors changed practice:
• ART effectiveness: modern regimens reliably suppress viral load and restore CD4 counts across nearly all adherent patients, removing the underlying driver of MAC risk far more completely than an antibiotic ever could • Time to benefit: rather than being a distant hope, meaningful CD4 recovery on modern ART often begins within weeks, shrinking the true "vulnerable window" during which prophylaxis would add protection • Avoiding unnecessary exposure: macrolide prophylaxis is not free of cost — added pill burden, drug interactions (notably with some ART components), and the theoretical risk of selecting macrolide-resistant organisms (including nontuberculous mycobacteria and other flora) argue against reflexive use when ART alone will resolve the risk
As a result, most current guidance no longer recommends prophylaxis by CD4 number alone — it is layered onto whether the patient is actually on, and responding to, effective ART.
The central practice principle is straightforward: promptly starting effective ART is now considered the primary and preferred MAC-prevention strategy for the great majority of newly or previously untreated patients with low CD4 counts. Rather than adding a separate prophylactic antibiotic while ART takes effect, the emphasis has shifted to minimizing any delay in ART initiation itself — treating the root cause of susceptibility rather than layering on additional prevention for a window that modern ART shrinks substantially.
The core modern principle: for most patients with CD4 <50, prompt initiation of effective ART — not routine azithromycin prophylaxis — is now the primary strategy for preventing disseminated MAC disease.
Primary MAC prophylaxis has not disappeared — it has been narrowed to a specific clinical gap: patients with CD4 <50 who, for whatever reason, are not yet benefiting from effective ART. This includes those not currently on ART, those on ART but not yet virologically suppressed, and those who cannot start therapy promptly due to access, adherence, tolerability, or other clinical barriers. In this specific window, azithromycin-based prophylaxis may still be considered as a bridge until ART can take hold.
The modern decision pathway for a patient with CD4 <50 runs roughly as follows:
1. Is effective ART already established and the patient virologically suppressed? → If yes, primary MAC prophylaxis is not routinely needed regardless of the CD4 number, because ART itself is providing the dominant protection and CD4 recovery is expected
2. Is the patient not on ART, not yet suppressed, or unable to start ART promptly (access barriers, tolerability issues, treatment interruption)? → In this scenario, azithromycin-based prophylaxis may be considered as a temporary bridge to reduce MAC risk during the vulnerable interval before ART restores immune competence
3. Once effective ART is established and suppression/CD4 recovery is underway, the ongoing need for prophylaxis is reassessed rather than continued indefinitely by default
Where prophylaxis is used, azithromycin is generally favored over clarithromycin for primary MAC prevention because of its once-weekly dosing, simpler regimen, more favorable drug-interaction profile, and comparable efficacy demonstrated in clinical trials from the pre-ART and early-ART eras. Clarithromycin remains an alternative but requires daily dosing and carries a greater burden of drug-drug interactions, which matters in patients simultaneously starting or adjusting ART regimens.
Because this indication is explicitly framed as a bridge — tied to the ART gap rather than to the CD4 number in isolation — prophylaxis in this scenario should be reassessed once the underlying gap (lack of ART, lack of suppression, inability to start therapy) is resolved.
For the majority of patients presenting with advanced immunosuppression, the single most important MAC-prevention action a clinician can take is minimizing delay to effective antiretroviral therapy. Because MAC risk is fundamentally a consequence of CD4 depletion, restoring CD4 count and immune function through viral suppression addresses the underlying vulnerability directly — rather than managing its downstream infectious consequence with an additional antibiotic.
Antiretroviral therapy suppresses HIV replication, halting the ongoing destruction of CD4+ T-cells and allowing gradual reconstitution of both cell numbers and functional immune responses. As CD4 counts climb — first often driven by redistribution of memory cells, later by genuine thymic and peripheral proliferation — the mucosal and systemic immune mechanisms that normally contain low-virulence organisms like MAC are progressively restored.
This is why rapid ART initiation is now considered prevention in its own right for MAC, rather than simply the "underlying treatment" running in parallel with a separate prophylactic drug. Guidelines increasingly emphasize minimizing time-to-ART-start across all opportunistic infection risk categories, MAC included, given how directly CD4 recovery maps onto declining MAC risk.
This shift has practical downstream effects on how care is organized:
• Same-day or rapid ART start programs are prioritized for newly diagnosed or re-engaging patients with low CD4 counts, since delay itself is now recognized as a modifiable risk factor for MAC and other opportunistic infections • Adherence support and addressing barriers to ART continuation (housing, mental health, substance use, insurance/access) become MAC-prevention interventions in a meaningful sense, not just general HIV care goals • Prophylaxis is reserved as a targeted, time-limited bridge rather than a default companion therapy — reducing pill burden and interaction risk while ART does the primary preventive work
Reframing rapid ART initiation as the primary MAC-prevention strategy reflects a broader shift in HIV care: treating the immunologic root cause is now more effective, and often simpler, than managing each downstream opportunistic infection risk with a separate prophylactic drug.
When primary MAC prophylaxis has been started — typically during a window of CD4 <50 with an ART gap — it does not need to continue indefinitely. Once the patient achieves and sustains meaningful immune reconstitution on effective ART, the risk that justified prophylaxis in the first place has resolved, and continued antibiotic exposure offers diminishing benefit relative to its costs.
The specific, widely used criterion for discontinuing primary MAC prophylaxis is a sustained CD4 count above 100 cells/mm³, maintained for three or more consecutive months, in a patient on effective (virologically suppressive) ART. This threshold — set safely above the original <50 risk trigger — provides a margin of confidence that immune reconstitution is durable rather than a transient fluctuation, before prophylaxis is withdrawn.
The logic mirrors similar secondary-prophylaxis-discontinuation rules used across other AIDS-defining opportunistic infections (e.g., PCP, toxoplasmosis prophylaxis): rather than continuing preventive antibiotics indefinitely once the underlying immunosuppression has resolved, guidelines define an evidence-based recovery threshold and duration at which the risk of disease recurrence becomes low enough that the marginal benefit of continued prophylaxis no longer outweighs its costs.
Stopping prophylaxis once it is no longer needed is not simply a matter of convenience:
• Reduced drug burden: fewer daily or weekly pills improves overall regimen simplicity and adherence to the ART regimen that matters most • Fewer drug interactions: macrolides interact with several antiretroviral and other medications; removing an unnecessary agent reduces interaction risk • Antimicrobial stewardship: unnecessary long-term macrolide exposure contributes to selection pressure for macrolide-resistant organisms, both mycobacterial and otherwise • Should CD4 subsequently fall back below the risk threshold (e.g., due to treatment interruption or virologic failure), prophylaxis can be restarted — the discontinuation decision is not irreversible, but conditional on sustained immune status
Discontinuation criterion: CD4 sustained >100 cells/mm³ for at least three consecutive months on effective, suppressive ART. Below this, or without ART suppression, prophylaxis (if indicated) should continue.